Paysign Insiders Made A Wise Decision By Selling US$743k Worth Of Stock
The article discusses how Paysign (NASDAQ:PAYS) insiders sold US$743k worth of stock over the last year at an average price of US$6.27. This selling activity, coupled with the stock's current trading price of US$3.88, suggests that the insiders made a timely decision, avoiding significant losses. The analysis also covers Paysign's earnings growth and valuation, noting the stock may be undervalued compared to its intrinsic value despite insider selling.
Paysign (NASDAQ:PAYS) Sets New 1-Year High - Here's What Happened
Paysign (NASDAQ:PAYS) recently hit a new 52-week high, trading at $14.93, driven by strong quarterly results where it exceeded EPS and revenue expectations. Analysts maintain a "Buy" rating with a consensus price target of $15.00, though insider selling of approximately $5.3 million occurred alongside increased institutional ownership.
Paysign (NASDAQ:PAYS) Stock Jumps 7.1% - Here's Why
Paysign (NASDAQ:PAYS) stock jumped 7.1% after receiving bullish analyst ratings and reporting strong quarterly results that beat expectations. Lake Street Capital and DA Davidson both raised their price targets to $15, aligning with the consensus "Buy" rating. The company also provided optimistic fiscal 2026 EPS guidance, despite recent insider share sales.
PAYS Maintained by DA Davidson -- Price Target Raised to $15.00
DA Davidson has maintained a 'Buy' rating for PaySign (PAYS) and raised its price target from $12.00 to $15.00, reflecting optimism about the company's growth potential. However, GuruFocus indicates that PAYS is 94.6% overvalued with a current price of $13.15 against a GF Value™ of $6.76, and insider activity shows significant selling. Despite strengths in profitability and financial stability, investors are advised to approach PAYS with caution due to its high valuation and cautious sentiment from institutional investors and insiders.
DA Davidson raises Paysign stock price target to $15 on growth outlook By Investing.com
DA Davidson has increased its price target for Paysign Inc. (NASDAQ: PAYS) to $15.00 from $12.00, reiterating a Buy rating. This adjustment follows a detailed analysis of the Patient Affordability niche and positive meetings with management, leading to increased confidence in the company's strong growth prospects. Paysign recently reported Q2 2026 earnings that surpassed Wall Street expectations, prompting the firm to raise its 2027 and introduce 2028 forecasts.
DA Davidson raises Paysign stock price target to $15 on growth outlook
DA Davidson has increased its price target for Paysign Inc. (NASDAQ:PAYS) to $15 from $12, maintaining a Buy rating, based on stronger growth prospects in the Patient Affordability niche. The firm also revised its 2027 forecasts and introduced 2028 forecasts. This follows Paysign's strong Q2 2026 earnings, which surpassed Wall Street expectations for both revenue and EPS, leading the company to raise its full-year outlook.
2ZE | Paysign Inc. Stock Overview (Germany: Frankfurt)
This article provides an overview of Paysign Inc. (2ZE) stock performance on the Frankfurt exchange, including key financial metrics like market value, EPS, and P/E ratio. It also lists the current stock price, day range, 52-week range, and trading volume. The data is presented with disclaimers about its informational purpose and sources.
Paysign Inc. Advanced Charts | 2ZE
This page provides advanced chart information for Paysign Inc. (2ZE) on the Frankfurt market. It displays real-time market data such as current price, daily range, 52-week range, volume, market value, EPS, and P/E ratio. The page also details the various data sources for the financial information provided.
Paysign (NASDAQ:PAYS): High-Growth Leadership With Strong Momentum
Paysign Inc. (NASDAQ: PAYS) exhibits strong growth potential based on a CAN SLIM analysis, showing exceptional quarterly and annual earnings and revenue growth, along with a robust return on equity and zero debt. While its technical performance is strong, valuation and supply-side concerns like share dilution present potential risks. The article recommends PAYS for a watchlist, suggesting a wait for a clearer entry point due to recent price volatility.
Paysign (NASDAQ:PAYS) EVP Joan Herman Sells 38,900 Shares
Paysign's EVP Joan Herman sold 38,900 shares of the company's stock for over $450,000 under a Rule 10b5-1 trading plan, retaining a significant stake worth approximately $7.15 million. The transaction follows a period where Paysign's stock performance has been strong, with shares rising 5.1% to $12.42, and the company exceeding quarterly EPS and revenue estimates. Analysts maintain a "Buy" rating for Paysign with a consensus target price of $14.00, reflecting confidence in its future performance.
Paysign (PAYS) ops chief sells nearly 60K shares under preset plan
Paysign, Inc. (PAYS) director and EVP of Operations, Joan M. Herman, sold a total of 59,904 shares of common stock in open-market transactions under a Rule 10b5-1 trading plan. The sales occurred on September 15 and 16, 2026, at weighted average prices of $12.3819 and $11.7437, respectively. These transactions were made according to a plan adopted on September 12, 2025.
Paysign EVP, operations Joan Herman sells $716,899 in shares
Joan Herman, EVP of Operations and a Director at Paysign Inc. (NASDAQ:PAYS), sold $716,899 worth of company stock in mid-September through two transactions, executed under a Rule 10b5-1 trading plan. These sales occurred as the stock trades near its 52-week high after a significant surge. Despite the insider sales and an InvestingPro analysis suggesting the stock is slightly overvalued, Paysign recently exceeded Q2 2026 earnings expectations and raised its full-year outlook.
Paysign EVP, operations Joan Herman sells $716,899 in shares By Investing.com
Joan M. Herman, EVP of Operations and a Director at Paysign, Inc. (NASDAQ:PAYS), sold common stock worth $716,899 in two transactions in mid-September. The sales were executed under a Rule 10b5-1 trading plan at weighted average prices between $11.7437 and $12.3819 per share, following a significant 286% surge in the stock over the past six months. Despite the sales, Ms. Herman still directly holds 609,421 shares of Paysign common stock, and the company recently surpassed Q2 2026 earnings expectations, raising its full-year outlook.
Paysign (PAYS) insider sells 150K shares, keeps 461K
Paysign's Chief Innovation Officer, Michael C. Ngo, indirectly sold a total of 150,000 shares of common stock through Gamma Innovation LLC on September 8-9, 2026, at weighted average prices of $12.8494 and $12.74 per share. These sales were open-market transactions and were not made under a Rule 10b5-1 trading plan. Despite the sales, Ngo retains a direct holding of 461,336 Paysign shares.
Paysign Insider Sold Shares Worth $1,918,666, According to a Recent SEC Filing
A Paysign insider sold shares totaling $1,918,666, as disclosed in a recent SEC filing. This transaction follows other insider share sales from Paysign in August, indicating ongoing insider activity. The company's stock, PAYS, was trading at $13.01 with a slight daily decrease as of September 11, 2026.
Enterprise value to EBIT forward of Paysign, Inc. – NASDAQ:PAYS
This article focuses on the enterprise value to EBIT forward of Paysign, Inc. (NASDAQ: PAYS). It provides financial data for the company, accessible through TradingView, a platform offering various market tools and data. The content highlights financial metrics without delving into specific analysis.
Asset deal gives Paysign (PAYS) innovation chief 3M restricted shares
Paysign, Inc.'s Chief Innovation Officer, Michael C. Ngo, received 3 million restricted shares in two grants: 2.5 million shares indirectly via Gamma Innovation LLC as part of an asset purchase agreement, and 500,000 shares directly. These shares are subject to vesting schedules, with some shares withheld by Paysign to cover tax obligations. Ngo is the sole owner of Gamma Innovation LLC, linking the indirect share grant directly to him.
Cunningham Bradley Kramer Surrenders 46,378 Shares of Paysign Inc.
Cunningham Bradley Kramer, Paysign Inc.'s Chief Technology Officer, has surrendered 46,378 shares of the company, with transaction prices ranging from $5.87 to $8.96. The article details Kramer's various holdings in Paysign, including distinct positions of 130,000, 30,000, 114,000, 33,334, and 66,666 shares. This surrender is part of the disclosed ownership information for Paysign (NASDAQ: PAYS).
PAYS: PaySign Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of PaySign Inc. (PAYS), including its latest stock price, market capitalization, key financial metrics, and company description. It also highlights recent news from Zacks, indicating positive analyst sentiment and growth potential for the stock. Investor sentiment and community polls are also presented.
Bank of America Corp DE Grows Stock Position in Paysign, Inc. $PAYS
Bank of America Corp DE significantly increased its stake in Paysign, Inc. by 345.9% in Q1, now holding 130,930 shares valued at $772,000. Despite this institutional interest, Paysign insiders have recently sold 345,000 shares worth $3.56 million. The company reported strong Q1 earnings, beating analyst estimates for both EPS and revenue, and analysts maintain a consensus "Buy" rating with an average price target of $13.33.
Paysign president Matthew Turner sells $62,637 in stock
Paysign President Matthew Turner recently engaged in stock transactions, including selling shares worth $62,637 to cover tax obligations and acquiring performance-based restricted stock. These activities follow a period of significant growth for Paysign, with its shares returning 156% over the past year. The company also reported strong Q2 2026 results, exceeding Wall Street expectations and raising its full-year outlook.
Paysign Targets $117M Revenue as Patient-Affordability Business Surges
Paysign (NASDAQ: PAYS) is projecting revenue between $114 million and $117 million for the current year, driven by significant growth in its patient-affordability business, which is expected to reach $60 million in revenue. The company also anticipates plasma revenue to hit nearly $57 million. Paysign attributes its financial strength to operating leverage from shared infrastructure and a robust balance sheet with over $30 million in unrestricted cash and no bank debt, supporting its expansion efforts in both healthcare-focused segments.
Are Business Services Stocks Lagging Paysign (PAYS) This Year?
Paysign, Inc. (PAYS) has significantly outperformed its Business Services peers and the broader sector this year, with its stock gaining 148.5% compared to the sector's average return of -8.5%. The company holds a Zacks Rank of #2 (Buy), driven by a 16% increase in its full-year earnings consensus estimate over the last quarter. Another notable outperformer in the sector is Sezzle Inc. (SEZL), which has returned 97.6% year-to-date and holds a Zacks Rank #1 (Strong Buy).
GSA Capital Partners LLP Buys Shares of 119,578 Paysign, Inc. $PAYS
GSA Capital Partners LLP has acquired a new stake of 119,578 shares in Paysign, Inc. (NASDAQ:PAYS) during the second quarter, valued at approximately $979,000. This makes GSA Capital Partners LLP an owner of 0.21% of Paysign's stock. Other institutional investors also increased their holdings, and the article details recent financial performance, analyst ratings, and insider trading activities for Paysign.
Paysign, Inc. to Present at the 17th Annual Midwest IDEAS Investor Conference
Paysign, Inc. announced its participation in the 17th Annual Midwest IDEAS Investor Conference, scheduled for August 26-27, 2026, in Chicago. Key executives, including CEO Mark Newcomer, CFO Jeff Baker, and Matt Turner, will attend to engage with institutional investors in one-on-one and group meetings. The conference provides a platform for quality public companies to connect with top investment professionals.
107,077 Shares in Paysign, Inc. $PAYS Acquired by OneDigital Investment Advisors LLC
OneDigital Investment Advisors LLC recently acquired 107,077 shares of Paysign, Inc. ($PAYS) valued at approximately $877,000, bringing institutional ownership to 25.89%. Despite recent insider stock sales by the CEO and CFO, the company reported strong Q2 earnings, exceeding analyst estimates, and analysts maintain a consensus "Buy" rating with an average price target of $13.33. Paysign, a financial technology company specializing in prepaid payment solutions, also issued positive fiscal 2026 EPS guidance.
Paysign CEO Mark Newcomer sells $1.78m in common stock
Paysign CEO Mark Newcomer sold 150,000 shares of the company's common stock for $1.78 million, executing the sale under a Rule 10b5-1 trading plan. This transaction occurred as Paysign's shares were trading near their 52-week high after a significant 289% surge in six months. The company recently reported strong Q2 2026 earnings, exceeding analyst expectations and raising its full-year outlook.
Paysign (NASDAQ:PAYS) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Paysign (NASDAQ:PAYS) from "strong-buy" to "buy," although the broader analyst consensus remains "Buy" with an average price target of $13.33. The company recently reported strong quarterly earnings, exceeding both EPS and revenue estimates, and issued positive fiscal 2026 EPS guidance. Despite these positive financial results, there have been significant insider stock sales totaling over $4 million in the past 90 days.
EBITDA of Paysign, Inc. – DUS:2ZE
This article provides financial information for Paysign, Inc. (DUS:2ZE) on the Dusseldorf Stock Exchange, specifically focusing on its EBITDA. The content appears to be a financial data page from TradingView, indicating no current trades for the company and offering various financial tools and market data services.
PaySign Inc (PAYS) CFO Jeffery Baker Sells 35,000 Shares
PaySign Inc's CFO, Jeffery Baker, sold 35,000 shares of PAYS on August 12, 2026, for approximately $441,700. This sale contributes to a broader trend of insider selling with no corresponding buying over the past year, suggesting that insiders might view the stock as overvalued. GuruFocus analysis supports this, indicating the stock is significantly overvalued with a price-to-GF-Value ratio of 1.93 and a high P/E ratio compared to its industry median.
Insider Selling: Paysign (NASDAQ:PAYS) CFO Sells $441,700.00 in Stock
Paysign (NASDAQ:PAYS) CFO Jeffery Bradford Baker sold 35,000 shares of the company's stock for $441,700.00. This transaction reduced his holdings by 6.06% to 542,171 shares. The sale occurred shortly after Paysign exceeded quarterly earnings expectations and provided positive fiscal 2026 guidance, with shares trading near their 52-week high.
Paysign (PAYS) CFO Baker sells 35,000 shares at $12.62 weighted average
Paysign, Inc.'s Chief Financial Officer, Jeffery Bradford Baker, reported selling 35,000 shares of common stock on August 12, 2026. The shares were sold at a weighted average price of $12.6182, with individual trades ranging from $12.54 to $12.72. Following this transaction, Baker directly holds 542,171 shares of Paysign common stock.
Pretax income of Paysign, Inc. – DUS:2ZE
This page displays financial information for Paysign, Inc. (DUS:2ZE) on the Dusseldorf Stock Exchange, specifically focusing on its pretax income. The article provides a high-level overview of the company's financials without specific figures. It also lists various features and services offered by TradingView.
Paysign, Inc. $PAYS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in Paysign, Inc. (NASDAQ:PAYS) by 16.8% in the first quarter, acquiring 82,736 shares to hold a total of 575,619 shares. This comes amidst insider selling by Director Bruce A. Mina and EVP Joan M. Herman, though company insiders still retain a significant ownership stake. Analysts maintain a "Buy" rating for Paysign, with a consensus price target of $13.33, following the company's recent earnings beat.
PaySign Inc (PAYS) CEO and 10% Owner Mark Newcomer Sells 150,000 Shares
PaySign Inc CEO and 10% owner Mark Newcomer sold 150,000 shares of PAYS on August 6, 2026, for approximately $1.78 million, bringing his total ownership to 9,163,002 shares. This sale is part of a broader trend of insider selling at PaySign, with no insider buys in the past year and 9 insider sells, while the stock is considered significantly overvalued according to GuruFocus's GF Value of $6.40 compared to its trading price of $11.88.
CEO stock sale: Paysign, Inc. (PAYS) chief sells 150,000 shares
Paysign, Inc.'s CEO, Mark Newcomer, sold 150,000 shares of common stock on August 6, 2026, at a weighted average price of $11.8757 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established in September 2025. Following the sale, Newcomer still directly holds over 9.1 million shares of the company.
Total debt per share of Paysign, Inc. – FWB:2ZE
This article provides the title "Total debt per share of Paysign, Inc. – FWB:2ZE" and indicates that the market is closed with no trades. It is a financial data page from TradingView for Paysign, Inc. on the Frankfurt Stock Exchange.
Paysign (PAYS) director converts 20,000-share grant, now holds 290,000
Paysign, Inc. director Dennis L. Triplett converted a 20,000-share stock grant into common stock on August 4, 2026. This transaction increased his direct holdings to 290,000 shares of Paysign common stock, following the vesting of the grant which was originally received on August 4, 2025. The conversion was made at $0.0000 per share and was not executed under a Rule 10b5-1 trading plan.
Paysign, Inc. (PAYS) director converts 20,000-share grant into stock
Paysign, Inc. director Henry Daniel R converted a 20,000-share stock grant into common stock on August 4, 2026, increasing his direct holdings to 169,884.498 shares. The grant, originally received on August 4, 2025, vested on August 4, 2026, with the transaction occurring at $0.00 per share. This insider transaction, identified by transaction code M, was not part of a Rule 10b5-1 trading plan.
Paysign (PAYS) director adds 20,000 vested shares, holdings reach 278,500
Paysign, Inc. director Bruce A. Mina acquired 20,000 shares of common stock through the vesting and conversion of a prior stock grant on August 04, 2026. This transaction increased his direct holdings of Paysign common stock to 278,500 shares. The original grant was made on August 04, 2025, and has now fully vested.
Paysign, Inc. (PAYS) director exercises 20,000-share grant, now holds 90,000
Paysign, Inc. director Jeffrey B. Newman exercised a stock grant of 20,000 derivative shares, converting them into 20,000 shares of common stock on August 4, 2026. The grant, awarded on August 4, 2025, fully vested by the filing date. Following this transaction, Newman directly owns 90,000 shares of Paysign common stock.
Paysign, Inc. 2026: Revenue $28.25M, EPS $0.11— 10-Q Summary
Paysign, Inc. (PAYS) reported strong financial results for the 2026 period, with revenue reaching $28.25 million and diluted EPS at $0.11. This significant year-over-year growth was driven by a 48.1% increase in total revenue, alongside a substantial rise in net income and diluted EPS. The company's performance was bolstered by expanded pharma and plasma program volumes, leading to investments in operational scaling.
Paysign, Inc. Stock 12‑Month Price Target Raised to $11.05, Implies 15% Upside
Paysign, Inc.'s average stock price target has been raised from $10.45 to $11.9 by five analysts, implying a 24% potential upside from its August 5th closing price. The consensus rating remains a "Buy" from all five covering analysts. This update suggests a strong positive outlook for the company's stock performance.
Paysign (NASDAQ:PAYS) Flashes Minervini-Style Momentum With Strong Uptrend and Accelerating Fundamentals
Paysign (NASDAQ:PAYS) exhibits strong Minervini-style momentum, characterized by a robust technical uptrend and accelerating fundamentals. The company meets the rigorous Trend Template criteria, showing significant price appreciation and rising moving averages, alongside impressive earnings and revenue growth. This combination suggests PAYS is a market leader with high relative strength and improving profitability, though investors should consider risk management for potential entry points.
Paysign, Inc. Stock 12‑Month Price Target Raised to $11.05, Implies 15% Upside
The average price target for Paysign, Inc. (PAYS) stock has increased from $10.45 to $11.9, according to estimates from 5 analysts. This updated target implies approximately a 24% potential upside based on the August 5 closing price. The consensus rating for PAYS remains a "Buy" from all 5 covering analysts.
PaySign Inc (PAYS) (Q2 2026) Earnings Call Highlights: Record Revenue Surges 48% as Patient ...
PaySign Inc (PAYS) reported record Q2 2026 results with total revenue surging 48.1% to $28.3 million, driven significantly by an 88.9% increase in Pharma Revenue. Net income nearly quintupled to $6.8 million, and adjusted EBITDA more than doubled to $9.6 million. The company also raised its full-year 2026 guidance, expecting continued strong growth in revenue and adjusted EBITDA, primarily due to the robust performance of its Patient Affordability segment and a healthy pipeline of new programs.
Paysign Q2 2026 Earnings: Pharma Growth Drives 48% Revenue Increase
Paysign (NASDAQ: PAYS) reported a 48.1% year-over-year revenue increase to $28.25 million in Q2 2026, driven primarily by growth in pharma patient affordability programs. This shift towards higher-margin pharma revenue also led to significant margin expansion, with GAAP diluted EPS rising to $0.11 from $0.02. The company raised its full-year 2026 revenue outlook to $114 million-$117 million and adjusted EBITDA outlook to $35 million-$38 million.
PAYS: Record revenue, margin expansion, and raised outlook driven by Patient Affordability growth
Paysign, Inc. (PAYS) reported record Q2 results, with 48% revenue growth and a 113% increase in adjusted EBITDA, primarily due to Patient Affordability and plasma recovery. The company raised its full-year guidance, expanded margins, and demonstrated platform scalability. This positive performance was highlighted during their Q2 2026 earnings call on August 5, 2026.
PaySign Inc (PAYS) (Q2 2026) Earnings Call Highlights: Record Revenue Surges 48% as Patient ...
PaySign Inc (PAYS) reported record second-quarter 2026 results, with total revenue surging 48.1% year-over-year to $28.3 million, driven primarily by an 88.9% increase in Pharma Revenue to $14.6 million. Net income saw a nearly five-fold increase to $6.8 million, and adjusted EBITDA rose by 113% to $9.6 million. The company raised its full-year 2026 guidance, expecting continued strong growth, but faces potential risks related to concentration in the patient affordability segment, delays in FDA approval for its Apherion BECS system, and rising operating expenses.
Earnings call transcript: Paysign tops Q2 2026 estimates and lifts outlook
Paysign Inc. reported strong second-quarter 2026 results, surpassing Wall Street's earnings and revenue estimates and leading to a raised full-year outlook. The company's performance was significantly driven by its patient affordability programs, which saw an 89% increase in revenue, and a recovery in its plasma business. Paysign's stock reacted positively, nearing its 52-week high, as management expressed confidence in continued growth and expanding margins.
